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Available online 28 February 2016AbstractBackground/Objective: Platelet-rich plasma (PRP) and hyaluronic acid (HA) injection are both therapeutic options for osteoarthritis and chronic
tendinopathy. Although several comparative studies on the two have been published, the effects of mixing PRP and HA are not fully understood.
The purpose of this study is to investigate the influence of HA on platelets in PRP by measuring releasing growth factors.
Methods: PRP was produced from nine healthy adult volunteers (mean age, 32.8± 2.9 years; range, 29e37) with a commercial separation
system. HA of weight-average molecular weight of 50e120 kDa was used. PRP group (PRP 1 mL þ phosphate buffered saline 0.2 mL) and PRP
þ HA group (PRP 1 mL þ HA 0.2 mL) were incubated at 37C for 2 hours. The amounts of transforming growth factor b1 (TGF-b1) and
platelet-derived growth factor (PDGF-AA) released from the PRP and PRP þ HA samples were measured on Day 0, Day 3, and Day 5. In
addition, the same growth factors on Day 5 were measured for PRP þ high HA group (PRP 1 mL þ HA 0.6 mL) with five donors. After
collecting all of the samples on Day 5, the remaining gels were observed with Giemsa stain. Statistical analyses were performed using paired t
tests to compare the PRP and HA groups at each time point, and a one-way analysis of variance (one-way ANOVA) with Tukey post hoc tests
was used to compare the PRP, PRP þ HA, and PRP þ high HA groups.
Results: The TGF-b1 concentrations in the PRP and PRP þ HA were 24.3 ± 7.2 mg/mL and 22.4 ± 1.8 mg/mL ( p¼ 0.689) on Day 0,
17.2± 13.9 mg/mL and 25.4± 7.1 mg/mL ( p¼ 0.331) on Day 3, and 12.7± 10.5 mg/mL and 33.7 ± 8.3 mg/mL ( p¼ 0.034) on Day 5. The TGF-
b1 concentrations on Day 5 were 24.1 ± 5.2 mg/mL (PRP group), 28.3 ± 2.4 mg/mL (PRP þ HA), and 31.9± 4.8 mg/mL (PRP þ high HA; one-
way ANOVA: p¼ 0.003; post hoc PRP vs. PRP þ HA: p¼ 0.016). The PDGF-AA concentrations in the PRP and PRP þ HA groups were
2.30± 1.21 mg/mL and 2.32 ± 0.79 mg/mL ( p¼ 0.931) on Day 0, 2.03± 0.53 mg/mL and 2.13 ± 0.73 mg/mL ( p¼ 0.500) on Day 3, and
1.51± 0.40 mg/mL and 2.00± 0.52 mg/mL ( p¼ 0.003) on Day 5. The PDGF-AA concentrations were 1.48± 0.46 mg/mL (PRP group),
1.94± 0.57 mg/mL (PRP þ HA), and 2.69 ± 0.70 mg/mL (PRP þ high HA; one-way ANOVA: p¼ 0.0002; PRP vs. PRP þ high HA: p¼ 0.002;
PRP þ HA vs. PRP þ high HA: p¼ 0.011) on Day 5. The PRP showed larger coagulated masses than the PRP þ HA. The high concentration
HA group had the smallest coagulated mass of all of the group.
Conclusion: The levels of growth factors released by PRP on Day 5 were increased by the addition of HA. A mixture of PRP and HA may be a
more effective therapy than PRP or HA alone for osteoarthritis and tendinopathy.
Copyright © 2016, Asia Pacific Knee, Arthroscopy and Sports Medicine Society. Published by Elsevier (Singapore) Pte Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The use of platelet-rich plasma (PRP) to treat musculo-
skeletal soft tissue injuries,1 bone grafts,2 osteoarthritis
(OA),3,4 and even skin ulcers5 is increasing. Although the
long-term effects of PRP remain controversial, the high con-
centration of autologous growth factors in PRP is expected to
reduce the time needed for healing based on the accumulated
basic and clinical research. Therefore, assessment of the levels
of growth factors released from PRP is important.
Hyaluronic acid (HA) is widely used to treat OA of the
knee.6 The beneficial effects of HA are attributed to its
function as a viscosupplement and its anti-inflammatory ac-
tivity. HA injection is also used to treat tendon and ligament
injuries and after surgery.7,8
Several reports that compare the clinical outcomes achieved
with HA and PRP for OA have been published.3,4 However,
the clinical results of simultaneous HA and PRP injections
have not yet been reported.
Recently, Chen et al9 published an in vitro study of the
synergistic anabolic actions of HA and PRP on cartilage
regeneration in OA. In that report, the combination of HA
and PRP reduced the levels of proinflammatory cytokines
and increased articular chondrocyte proliferation and chon-
drogenic differentiation. The authors concluded that the
observed synergistic effects were the result of different
molecular mechanisms: the HA-dependent Erk1/2 pathway
and the PRP-dependent Smad2/3 pathway. However, the
direct influence of HA on the platelets in PRP was not dis-
cussed. In the present study, we tested the hypothesis that the
addition of HA increases the levels of growth factors
released by PRP.
Materials and methods
The protocol for this study was approved by the Ethics
Committee of Hirosaki University Graduate School of Medi-
cine, Aomori, Japan.Preparation of PRPNine healthy adult volunteers (2 women and 7 men) with an
average age of 32.8± 2.9 years (range, 29e37 years) were
included in this study. Only one patient was taking medication
of any kind, and that person was taking purgative medicine.
No impairment of liver or kidney functions was detected in the
patient blood samples.
Forty-five mL of peripheral blood for PRP preparation and
an additional 1 mL of blood for the whole blood cell count
were collected from the median cubital veins of each donor
using a 21-gauge needle. No anticoagulant or activation ma-
terials, such as calcium chloride, were used. The PRP was
produced using a commercial PRP separation system (Arthrex
ACP; Arthrex, Naples, FL, USA) using a double syringe
system according to the manufacturer's instructions. From
each donor, 10e12 mL of PRP was prepared. Blood counts for
the PRP preparations were measured using 1 mL of PRP.PRP culture and harvest of released growth factorsARTZ-Dispo HA (Seikagaku, Tokyo, Japan) with a weight-
average molecular weight of 50e120 kDa was used as the HA.
Three replicate wells of 1 mL of PRP and 0.2 mL of phosphate
buffered saline (PBS; PRP group), three replicate wells of
1 mL of PRP and 0.2 mL of HA (PRP þ HA group), and one
well of 1 mL of PRP and 0.6 mL of HA (PRP þ high HA
group) were incubated on noncoated six-well dishes (Nunc,
Shanghai, China) in a cell culture incubator at 37C with 5%
of CO2 immediately after PRP preparation. After 2 hours of
incubation (defined as Day 0), all the specimens had formed
gels. At that time, 8.8 mL of PBS was added to one well from
the PRP and PRP þ HA groups to a 10-fold dilution, and all
the liquid was collected 1 hour later. Any remaining platelets
were removed with gentle centrifugation for 15 minutes at
200g and then another centrifugation for 15 minutes at
10,000g. The samples were immediately frozen with liquid
nitrogen and stored at 80C until the growth factors were
assessed. In the same way, samples from the PRP and PRP þ
HA groups were obtained on Day 3 and Day 5 after PRP
preparation.
For five of the donor PRPs (n¼ 5 donors), the PRP þ high
HA group samples obtained on Day 5 were diluted with
8.4 mL of PBS because of the higher dose of 0.6 mL of HA. In
addition, to confirm that the growth factors were continuously
released from the PRP, 0.2 mL of PBS for the PRP group and
0.2 mL of HA for the HA group was added to the remaining
gels (n¼ 5 per group) after sample collection on Day 0 and
Day 3. The released growth factors were collected on Day 3
(Days 0e3) and Day 5 (Days 3e5) in a similar way as was
done for the PRP and PRP þ HA groups.Gross appearance on Day 5After collecting all of the samples, the remaining gels were
fixed with absolute methanol for 5 minutes and Giemsa stained
for 5 minutes. Microscopic images (Olympus IMT-2-21 RFM;
Olympus Corp., Tokyo, Japan) were taken using a digital
camera (Canon DS 126181; Canon Inc., Tokyo, Japan).HaematologyThe platelet, white blood cell, neutrophil, lymphatic cell,
and red blood cell counts in the peripheral blood and PRP
were determined using an automated cell count analyser
(Sysmex XE-5000; Sysmex Corp., Kobe, Japan).Transforming growth factor-b1 and platelet-derived
growth factor-AA levelsAfter thawing the stored samples, quantitative de-
terminations of the transforming growth factor-b1 (TGF-b1)
and platelet-derived growth factor-AA (PDGF-AA) levels
were performed using a commercially available enzyme-
linked immunosorbent assay kit (R&D Systems, Minneap-
olis, MN, USA) according to the manufacturer's instructions.
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spectrophotometer (Multiskan FC; Thermo Fisher Scientific,
Yokohama, Japan) at 450 nm with a wavelength correction of
570 nm. The final calculations were made using 10-fold
sample dilutions.Statistical analysisAll data are expressed as mean ± standard deviation. The
statistical analyses were performed using paired t tests to
compare the PRP and HA groups at each time point, and a
one-way analysis of variance (one-way ANOVA) with Tukey
posthoc tests was used to compare the PRP, PRP þ HA, and
PRP þ high HA groups. A p value < 0.05 was considered
statistically significant. All statistical analyses were performed
in GraphPad Prism 6.0 (GraphPad Software, San Diego, CA,
USA).
ResultsBlood cell countsThe concentrations of platelets and WBCs in the PRP
preparations were 2.35 ± 0.30 times and 0.305± 0.152 times
those found in the peripheral blood. The percentage of lym-
phocytes was higher in the PRP preparations (Table 1).Gross appearance at Day 5The PRP group showed larger coagulated masses than the
PRP þ HA group. The PRP þ high HA group had the smallest
coagulated mass of all of the groups (Figure 1).Growth factor concentrationsThe TGF-b1 concentrations in the PRP and PRP þ HA
were 24.3± 7.2 mg/mL and 22.4± 1.8 mg/mL ( p¼ 0.689) on
Day 0, 17.2 ± 13.9 mg/mL and 25.4± 7.1 mg/mL ( p¼ 0.331)
on Day 3, and 12.7± 10.5 mg/mL and 33.7± 8.3 mg/mL
( p¼ 0.034) on Day 5 (Figure 2A). The TGF-b1 concentra-
tions on Day 5 were 24.1± 5.2 mg/mL (PRP group),
28.3± 2.4 mg/mL (PRP þ HA), and 31.9± 4.8 mg/mL (PRP þ
high HA; one-way ANOVA: p¼ 0.003; posthoc PRP vs. PRP
þ HA: p¼ 0.016; Figure 3A).
The PDGF-AA concentrations in the PRP and PRP þ HA
groups were 2.30± 1.21 mg/mL and 2.32± 0.79 mg/mL
( p¼ 0.931) on Day 0, 2.03± 0.53 mg/mL and 2.13± 0.73 mg/
mL ( p¼ 0.500) on Day 3, and 1.51± 0.40 mg/mL and
2.00± 0.52 mg/mL ( p¼ 0.003) on Day 5 (Figure 2B). TheTable 1
Cell counts from the platelet-rich plasma and peripheral blood.
Platelets
( 1012/L)
WBC
( 109 cells/L)
Neutrophils
(% of WBC)
Lymphocyte
(% of WBC
PRP 4.68± 0.95 1.53± 0.64 15.2± 7.8 77.3± 8.2
PB 2.13± 0.53 5.15± 0.97 55.6± 22.1 27.1± 12.9
Hb¼ hemoglobin; PB¼ peripheral blood; PRP¼ platelet-rich plasma; RBC¼ redPDGF-AA concentrations were 1.48± 0.46 mg/mL (PRP
group), 1.94± 0.57 mg/mL (PRP þ HA), and 2.69 ± 0.70 mg/
mL (PRP þ high HA; one-way ANOVA: p¼ 0.0002; PRP vs.
PRP þ high HA: p¼ 0.002; PRP þ HA vs. PRP þ high HA:
p¼ 0.011) on Day 5 (Figure 3B).
The TGF-b1 and PDGF-AA levels on Day 3 after the wells
were washed on Day 0 (PRP Days 0e3, PRP þ HA Days
0e3) were more than half of that found on Day 3 without
washing. Those on Day 5 after being washed on Day 3 (PRP
Days 3e5, PRP þ HA Days 3e5) were also more than half of
those on Day 5 without washing out (Figure 4), which sug-
gests that the TGF-b1 and PDGF-AA were continuously
released from the PRP gels until at least 5 days after
incubation.
Discussion
PRP can stimulate the healing process of different tissues
by delivering various growth factors and cytokines that are
released by platelets. In the present study, we hypothesized
that adding HA to the PRP would increase the concentration of
growth factors released. This hypothesis was correct on Day 5,
but not on Day 0 or Day 3. These findings suggest that stim-
ulatory effect of HA on growth factor release seems to appear
slowly. Frelinger et al10 suggested that pulse electric field may
cause a selective permeabilization of specific granules or
populations of a granules. In this study, after removing growth
factors in the supernatant, both TGF-b1 and PDGF-AA were
released from platelets and the concentrations were elevated
close to Day 0 levels. Platelets may detect the surrounding
growth factor concentrate and release growth factors depend-
ing on the concentrate. Surrounding HA possibly affects the
selective permeabilization and population of a granules.
Activated platelets also form CD41 microparticles, which
function as a transport and delivery system for bioactive
molecules, participating in haemostasis and thrombosis,
inflammation, malignancy infection transfer, angiogenesis,
and immunity.11 Hu et al12 showed that the expression of P-
selectin dramatically increased after PRP interacted with
biomacromolecule complex film (HAecollagen (I)/chitosan).
HA engagement of CD44 leads to MAP kinase-dependent
increased trafficking of TGF-b receptors to lipid raft-
associated pools, which facilitates increased receptor turn-
over and attenuation of TGF-b1-dependent alteration in
proximal tubular cell function. Further investigation is need to
elucidate the mechanism on growth factor delivery.
Fibrin networks are formed by the conversion of fibrinogen.
Different fibre diameters, mass/length ratios, densities, po-
rosities, and permeabilities of the fibrin networks can alter cells
)
Monocytes
(% of WBC)
Eosinophils
(% of WBC)
Basophils
(% of WBC)
RBC
( 1012/L)
6.8± 2.7 0.1± 0.4 0.5± 0.4 0.31± 0.12
4.2± 1.0 2.4± 1.7 0.4± 0.2 56.1± 10.2
blood cells; WBC¼white blood cells.
Figure 1. Morphology of the platelet-rich plasma (PRP) gels on Day 5. The gels placed in wells were stained after all measurements with Giemsa stain (n¼ 5). (A)
PRP group; (B) PRP þ hyaluronic acid (HA) group; and (C) PRP þ high HA group. The size of the stained clots inside the gels was decreased in the samples with
higher HA concentrations.
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PRP preparations made different fibrin networks. In the pre-
sent study, smaller fibrin clots were observed in the HA group
than in the other groups. Srinivasan et al15 reported that hep-
arin sulfate proteoglycan (Perlecan/HSPG2) protects bone
morphogenetic protein 2 (BMP2) from proteolytic cleavage
through storing and controlling the release kinetics of BMP2,
which reduced knee OA in mice. Viscosupplementation with
HA may inhibit the aggregation of platelets and may affect the
delivery of growth factors.
HA has been widely used to treat OA, especially in Japan.6
HA provides viscoelastic properties to the synovial fluid andFigure 2. Comparison of the concentration of growth factors between the
platelet-rich plasma (PRP) alone and hyaluronic acid (HA) groups (n¼ 9). (A)
The transforming growth factor b1 (TGF-b1) level in the PRP þ HA group
was higher than that in the PRP group on Day 5. (B) The platelet-derived
growth factor (PDGF-AA) level in the PRP þ HA group was higher than
that in the PRP group on Day 5. * p< 0.005.contributes to boundary lubrication.16 HA demonstrates
several pleiotropic signalling properties, including anti-
inflammatory, antiapoptotic, antiangiogenic, and antifibrotic
effects on animal models of OA.17 HA also has analgesic
properties with a specific activity on opioid receptors.18,19
Chen et al9 showed, in an in vitro study, the synergistic
anabolic actions of HA and PRP on cartilage regeneration in
OA. In that report, a combination of HA and PRP reduced the
proinflammatory cytokines and increased articular chon-
drocyte proliferation and chondrogenic differentiation via the
HA-dependent Erk1/2 pathway and the PRP-dependent
Smad2/3 pathway. Together, those reports and our resultsFigure 3. Comparison of the concentration of growth factors with hyaluronic
acid (HA) concentration on Day 5 (n¼ 5). (A) The transforming growth factor
b1 (TGF-b1) level in the platelet-rich plasma (PRP) þ high HA group was
higher than that in the PRP group. (B) The platelet-derived growth factor
(PDGF-AA) level in the PRP þ high HA group was higher than that in the
PRP and PRP þ HA groups. * p < 0.005.
Figure 4. Growth factor release between the observation time points (n¼ 5).
Day 0e3 samples were assessed on Day 3 after being washed on Day 0, and
Day 3e5 samples were assessed on Day 5 after being washed on Day 3. (A)
Transforming growth factor b1 (TGF-b1) and (B) platelet-derived growth
factor (PDGF-AA) levels were assayed, and all the values were more than half
of that of the same condition when assessed without being washed out.
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may be more effective than either PRP or HA alone for certain
tissues.
There were several limitations to the present study. First,
we only examined two of the many potential growth factors,
such as epidermal growth factor, fibroblast growth factor,
vascular endothelial growth factor, or insulin-like growth
factor. We selected TGF-b1 and PDGF for analysis because
those are two of the most widely studied growth factors that
play central roles in tissue regeneration. However, the effects
of HA on the release of other growth factors may be different
than the results obtained for those two. Second, only two fe-
male donors were included in this study. Sex differences may
have influenced the results, although Weibrich et al20 found no
effect of sex on growth factor concentration. Third, we showed
only five donors data of high HA group. This group was added
after first four donors sample data examined. Finally, the PRP
samples were produced at different times, and circadian
rhythms may have influenced the data. However, Aoto et al21
reported that there were no significant diurnal variations in the
release of TGF-b1 and PDGF-BB.
In conclusion, HA increased the release of TGF-b1 and
PDGF-AA from PRP on Day 5. Thus, a mixture of PRP and
HA may result in an enhanced the healing effect on certain
tissues.
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